Argyrios Ziogas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9350049/publications.pdf

Version: 2024-02-01

250 papers 17,692 citations

67 h-index 123 g-index

256 all docs

256 docs citations

times ranked

256

21280 citing authors

#	Article	IF	Citations
1	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	27.8	1,099
2	Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies. Lancet Oncology, The, 2012, 13, 385-394.	10.7	753
3	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	6.2	711
4	Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies. Journal of the National Cancer Institute, 2011, 103, 250-263.	6.3	596
5	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	21.4	493
6	Lower Cancer Incidence in Amsterdam-I Criteria Families Without Mismatch Repair Deficiency. JAMA - Journal of the American Medical Association, 2005, 293, 1979.	7.4	491
7	Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nature Genetics, 2009, 41, 585-590.	21.4	434
8	Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. Journal of the National Cancer Institute, $2015,107,100$	6.3	428
9	A Population-Based Study of Genes Previously Implicated in Breast Cancer. New England Journal of Medicine, 2021, 384, 440-451.	27.0	414
10	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
11	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics, 2013, 45, 362-370.	21.4	326
12	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nature Genetics, 2010, 42, 874-879.	21.4	321
13	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
14	A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nature Genetics, 2009, 41, 996-1000.	21.4	276
15	Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nature Genetics, 2012, 44, 312-318.	21.4	256
16	Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nature Genetics, 2010, 42, 880-884.	21.4	235
17	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
18	Validation of family history data in cancer family registries. American Journal of Preventive Medicine, 2003, 24, 190-198.	3.0	220

#	Article	IF	CITATIONS
19	Delay in Surgical Treatment and Survival After Breast Cancer Diagnosis in Young Women by Race/Ethnicity. JAMA Surgery, 2013, 148, 516.	4.3	205
20	Adherence to Treatment Guidelines for Ovarian Cancer as a Measure of Quality Care. Obstetrics and Gynecology, 2013, 121, 1226-1234.	2.4	191
21	Aspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drug, and Acetaminophen Use and Risk of Invasive Epithelial Ovarian Cancer: A Pooled Analysis in the Ovarian Cancer Association Consortium. Journal of the National Cancer Institute, 2014, 106, djt431-djt431.	6.3	186
22	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nature Genetics, 2018, 50, 968-978.	21.4	184
23	Active Smoking, Household Passive Smoking, and Breast Cancer: Evidence From the California Teachers Study. Journal of the National Cancer Institute, 2004, 96, 29-37.	6.3	175
24	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	3.2	174
25	Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocrine-Related Cancer, 2013, 20, 251-262.	3.1	169
26	<i>CHEK2</i> *1100delC Heterozygosity in Women With Breast Cancer Associated With Early Death, Breast Cancerâ€"Specific Death, and Increased Risk of a Second Breast Cancer. Journal of Clinical Oncology, 2012, 30, 4308-4316.	1.6	162
27	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	9.4	157
28	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2011, 20, 3289-3303.	2.9	152
29	Age- and Tumor Subtype–Specific Breast Cancer Risk Estimates for <i>CHEK2</i> *1100delC Carriers. Journal of Clinical Oncology, 2016, 34, 2750-2760.	1.6	152
30	Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis, 2014, 35, 1012-1019.	2.8	145
31	Prognostic Factors for Survival in Extensive Stage Small Cell Lung Cancer (ED-SCLC): The Importance of Smoking History, Socioeconomic and Marital Statuses, and Ethnicity. Journal of Thoracic Oncology, 2009, 4, 37-43.	1.1	144
32	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications, 2013, 4, 1628.	12.8	144
33	Analysis of prognostic factors in Ewing sarcoma using a populationâ€based cancer registry. Cancer, 2010, 116, 1964-1973.	4.1	143
34	High-volume ovarian cancer care: Survival impact and disparities in access for advanced-stage disease. Gynecologic Oncology, 2014, 132, 403-410.	1.4	141
35	Evidence of Gene–Environment Interactions between Common Breast Cancer Susceptibility Loci and Established Environmental Risk Factors. PLoS Genetics, 2013, 9, e1003284.	3.5	136
36	Aurora- A/STK15 T \pm 91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis, 2005, 26, 1368-1373.	2.8	132

#	Article	IF	CITATIONS
37	Dietary Fat, Fiber, Vegetable, and Micronutrients Are Associated With Overall Survival in Postmenopausal Women Diagnosed With Breast Cancer. Nutrition and Cancer, 2006, 55, 132-140.	2.0	125
38	Japanese Ethnicity Compared with Caucasian Ethnicity and Never-Smoking Status Are Independent Favorable Prognostic Factors for Overall Survival in Non-small Cell Lung Cancer: A Collaborative Epidemiologic Study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry Databases. Journal of Thoracic Oncology, 2010, 5, 1001-1010.	1.1	125
39	Nonsteroidal Anti-Inflammatory Drug Use and Breast Cancer Risk by Stage and Hormone Receptor Status. Journal of the National Cancer Institute, 2005, 97, 805-812.	6.3	123
40	Epidemiology of Bronchioloalveolar Carcinoma: Improvement in Survival After Release of the 1999 WHO Classification of Lung Tumors. Journal of Clinical Oncology, 2005, 23, 8396-8405.	1.6	122
41	Asian Ethnicity Is a Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer (NSCLC) and Is Independent of Smoking Status. Journal of Thoracic Oncology, 2009, 4, 1083-1093.	1.1	113
42	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 1619-1630.	1.9	111
43	Low socioeconomic status is a poor prognostic factor for survival in stage I nonsmall cell lung cancer and is independent of surgical treatment, race, and marital status. Cancer, 2008, 112, 2011-2020.	4.1	110
44	Adenomyosis and endometriosis in the California Teachers Study. Fertility and Sterility, 2008, 90, 415-424.	1.0	109
45	Validity of Models for Predicting BRCA1 and BRCA2 Mutations. Annals of Internal Medicine, 2007, 147, 441.	3.9	106
46	Tumor Subsite Location Within the Colon Is Prognostic for Survival After Colon Cancer Diagnosis. Diseases of the Colon and Rectum, 2009, 52, 1359-1366.	1.3	103
47	19p13.1 Is a Triple-Negative–Specific Breast Cancer Susceptibility Locus. Cancer Research, 2012, 72, 1795-1803.	0.9	100
48	Spatial analysis of adherence to treatment guidelines for advanced-stage ovarian cancer and the impact of race and socioeconomic status. Gynecologic Oncology, 2014, 134, 60-67.	1.4	99
49	Protein Alterations Associated with Pancreatic Cancer and Chronic Pancreatitis Found in Human Plasma using Global Quantitative Proteomics Profiling. Journal of Proteome Research, 2011, 10, 2359-2376.	3.7	98
50	Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind FOXA1 and E2F1. American Journal of Human Genetics, 2013, 93, 1046-1060.	6.2	98
51	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications, 2013, 4, 1627.	12.8	98
52	Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Research, 2014, 16, 3419.	5.0	97
53	Sociodemographic Disparities in Advanced Ovarian Cancer Survival and Adherence to Treatment Guidelines. Obstetrics and Gynecology, 2015, 125, 833-842.	2.4	97
54	Adipose tissue levels of organochlorine pesticides and polychlorinated biphenyls and risk of non-Hodgkin's lymphoma Environmental Health Perspectives, 2004, 112, 854-861.	6.0	96

#	Article	IF	CITATIONS
55	Diet and Risk of Ovarian Cancer in the California Teachers Study Cohort. American Journal of Epidemiology, 2007, 165, 802-813.	3.4	96
56	Impact of National Cancer Institute Comprehensive Cancer Centers on Ovarian Cancer Treatment and Survival. Journal of the American College of Surgeons, 2015, 220, 940-950.	0.5	94
57	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	12.8	90
58	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	12.8	88
59	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. International Journal of Epidemiology, 2019, 48, 795-806.	1.9	81
60	Characterization of Hereditary Nonpolyposis Colorectal Cancer Families From a Population-Based Series of Cases. Journal of the National Cancer Institute, 2000, 92, 1517-1522.	6.3	80
61	Rrp1b, a New Candidate Susceptibility Gene for Breast Cancer Progression and Metastasis. PLoS Genetics, 2007, 3, e214.	3.5	80
62	The role of genetic breast cancer susceptibility variants as prognostic factors. Human Molecular Genetics, 2012, 21, 3926-3939.	2.9	80
63	Outcomes of Bariatric Surgery Performed at Accredited vs Nonaccredited Centers. Journal of the American College of Surgeons, 2012, 215, 467-474.	0.5	78
64	<i>ESR1/SYNE1</i> Polymorphism and Invasive Epithelial Ovarian Cancer Risk: An Ovarian Cancer Association Consortium Study. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 245-250.	2.5	75
65	Association between insurance and socioeconomic status and risk of advanced stage Hodgkin lymphoma in adolescents and young adults. Cancer, 2012, 118, 6179-6187.	4.1	74
66	Impact of race, socioeconomic status, and the health care system on the treatment of advanced-stage ovarian cancer in California. American Journal of Obstetrics and Gynecology, 2015, 212, 468.e1-468.e9.	1.3	73
67	Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortiumâ€. Human Molecular Genetics, 2011, 20, 4693-4706.	2.9	71
68	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 884-895.	1.9	71
69	Breast Cancer Risk and Methylenetetrahydrofolate Reductase Polymorphism. Breast Cancer Research and Treatment, 2003, 77, 217-223.	2.5	69
70	Risk and risk reduction involving arginine intake and meat consumption in colorectal tumorigenesis and survival. International Journal of Cancer, 2007, 120, 459-468.	5.1	68
71	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Human Molecular Genetics, 2015, 24, 5955-5964.	2.9	68
72	Genetic modifiers of CHEK2*1100delC-associated breast cancer risk. Genetics in Medicine, 2017, 19, 599-603.	2.4	67

#	Article	IF	Citations
73	Sex differences in the association of cutaneous melanoma incidence rates and geographic ultraviolet light exposure. Journal of the American Academy of Dermatology, 2017, 76, 499-505.e3.	1.2	66
74	Breast Cancer Survival and Hormone Replacement Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2000, 23, 541-545.	1.3	65
75	Prognostic Significance of the Non–Size-Based AJCC T2 Descriptors. Chest, 2008, 133, 662-669.	0.8	63
76	Single Nucleotide Polymorphisms in the <i>TP53</i> Region and Susceptibility to Invasive Epithelial Ovarian Cancer. Cancer Research, 2009, 69, 2349-2357.	0.9	63
77	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications, 2015, 6, 8234.	12.8	63
78	Pelvic Inflammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors: A Pooled Analysis of 13 Case-Control Studies. American Journal of Epidemiology, 2017, 185, 8-20.	3.4	61
79	Repair of Retinal Detachment Caused by Cytomegalovirus Retinitis in Patients With the Acquired Immunodeficiency Syndrome. American Journal of Ophthalmology, 1991, 112, 235-242.	3.3	60
80	Nonsteroidal antiâ€inflammatory drugs. Cancer, 2009, 115, 5662-5671.	4.1	59
81	Residential proximity to agricultural pesticide use and incidence of breast cancer in the California Teachers Study cohort. Environmental Research, 2004, 96, 206-218.	7.5	58
82	Population–Based Evaluation of Adenosquamous Carcinoma of the Colon and Rectum. Diseases of the Colon and Rectum, 2012, 55, 509-514.	1.3	58
83	Combined and Interactive Effects of Environmental and GWAS-Identified Risk Factors in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 880-890.	2.5	54
84	Hypertension, antihypertensive medication use, and breast cancer risk in the California Teachers Study cohort. Cancer Causes and Control, 2010, 21, 1615-1624.	1.8	53
85	Korean Ethnicity as Compared with White Ethnicity Is an Independent Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer before and after the Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Era. Journal of Thoracic Oncology, 2010, 5, 1185-1196.	1.1	52
86	Gene-Environment Interactions in Renal Cell Carcinoma. American Journal of Epidemiology, 2001, 153, 851-859.	3.4	51
87	Socioeconomic status as a predictor of adherence to treatment guidelines for early-stage ovarian cancer. Gynecologic Oncology, 2015, 138, 121-127.	1.4	49
88	Evaluation of Candidate Stromal Epithelial Cross-Talk Genes Identifies Association between Risk of Serous Ovarian Cancer and TERT, a Cancer Susceptibility "Hot-Spot― PLoS Genetics, 2010, 6, e1001016.	3.5	48
89	Association Between a Germline OCA2 Polymorphism at Chromosome 15q13.1 and Estrogen Receptor–Negative Breast Cancer Survival. Journal of the National Cancer Institute, 2010, 102, 650-662.	6.3	48
90	Risk of Ovarian Cancer and the NF-κB Pathway: Genetic Association with <i>IL1A</i> and <i>TNFSF10</i> Cancer Research, 2014, 74, 852-861.	0.9	48

#	Article	IF	Citations
91	The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing. Clinical Cancer Research, 2011, 17, 3742-3750.	7.0	47
92	Wine and other alcohol consumption and risk of ovarian cancer in the California Teachers Study cohort. Cancer Causes and Control, 2007, 18, 91-103.	1.8	46
93	Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung. Journal of Thoracic Oncology, 2010, 5, 420-427.	1.1	45
94	Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. Journal of the National Cancer Institute, 2021, 113, 329-337.	6.3	45
95	Microvascular Breast Reconstruction in the Diabetic Patient. Plastic and Reconstructive Surgery, 2007, 119, 38-45.	1.4	44
96	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS ONE, 2015, 10, e0128106.	2.5	44
97	Disparities in Adherence to National Comprehensive Cancer Network Treatment Guidelines and Survival for Stage IB–IIA Cervical Cancer in California. Obstetrics and Gynecology, 2018, 131, 899-908.	2.4	43
98	Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. Human Molecular Genetics, 2009, 18, 2297-2304.	2.9	42
99	Clinically Relevant Changes in Family History of Cancer Over Time. JAMA - Journal of the American Medical Association, 2011, 306, 172-8.	7.4	40
100	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. Human Molecular Genetics, 2015, 24, 3595-3607.	2.9	40
101	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. American Journal of Human Genetics, 2020, 107, 837-848.	6.2	39
102	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. American Journal of Human Genetics, 2015, 97, 22-34.	6.2	37
103	Evidence of a genetic link between endometriosis and ovarian cancer. Fertility and Sterility, 2016, 105, 35-43.e10.	1.0	37
104	Associations of a Polymorphism in the Ornithine Decarboxylase Gene with Colorectal Cancer Survival. Clinical Cancer Research, 2009, 15, 6208-6216.	7.0	35
105	11q13 is a susceptibility locus for hormone receptor positive breast cancer. Human Mutation, 2012, 33, 1123-1132.	2.5	35
106	Impact of community disadvantage and air pollution burden on geographic disparities of ovarian cancer survival in California. Environmental Research, 2017, 156, 388-393.	7.5	34
107	Racial and Socioeconomic Disparities in Bladder Cancer Survival: Analysis of the California Cancer Registry. Clinical Genitourinary Cancer, 2019, 17, e995-e1002.	1.9	34
108	Missense Variants in $\langle i \rangle$ ATM $\langle i \rangle$ in 26,101 Breast Cancer Cases and 29,842 Controls. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2143-2151.	2.5	33

#	Article	IF	Citations
109	The association of body mass index with mortality in the California Teachers Study. International Journal of Cancer, 2011, 129, 2492-2501.	5.1	33
110	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 2015, 21, 5264-5276.	7.0	33
111	Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. International Journal of Epidemiology, 2018, 47, 460-472.	1.9	33
112	A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46 450 cases and 42 461 controls from the breast cancer association consortium. Human Molecular Genetics, 2014, 23, 1934-1946.	2.9	32
113	Risk Prediction for Epithelial Ovarian Cancer in 11 United States–Based Case-Control Studies: Incorporation of Epidemiologic Risk Factors and 17 Confirmed Genetic Loci. American Journal of Epidemiology, 2016, 184, 555-569.	3.4	32
114	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	1.3	32
115	Validation of the Proposed International Association for the Study of Lung Cancer Non-small Cell Lung Cancer Staging System Revisions for Advanced Bronchioloalveolar Carcinoma Using Data from the California Cancer Registry. Journal of Thoracic Oncology, 2007, 2, 1078-1085.	1.1	31
116	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. Nature Communications, 2020, 11, 312.	12.8	30
117	A resource utilization projection study of EUS. Gastrointestinal Endoscopy, 2002, 55, 328-334.	1.0	29
118	Differential Effects of Wine Consumption on Colorectal Cancer Outcomes Based on Family History of the Disease. Nutrition and Cancer, 2007, 59, 36-45.	2.0	28
119	Network-Based Integration of GWAS and Gene Expression Identifies a <i>HOX</i> -Centric Network Associated with Serous Ovarian Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1574-1584.	2.5	28
120	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38.	5.2	28
121	Dietary Patterns and Risk of Ovarian Cancer in the California Teachers Study Cohort. Nutrition and Cancer, 2008, 60, 285-291.	2.0	27
122	Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor–Positive, Lower Grade Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2222-2231.	2.5	27
123	Treatment for T1a Renal Cancer Substratified by Size: "Less is More― Journal of Urology, 2016, 196, 1000-1007.	0.4	26
124	Feasibility of Management of High-Grade Cervical Lesions in a Single Visit. JAMA - Journal of the American Medical Association, 2005, 294, 2182.	7.4	25
125	Attitudes Toward Cancer Clinical Trial Participation in Young Adults with a History of Cancer and a Healthy College Student Sample: A Preliminary Investigation. Journal of Adolescent and Young Adult Oncology, 2014, 3, 20-27.	1.3	25
126	Spatial analysis of advanced-stage ovarian cancer mortality in California. American Journal of Obstetrics and Gynecology, 2015, 213, 43.e1-43.e8.	1.3	25

#	Article	IF	Citations
127	Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. International Journal of Cancer, 2017, 140, 2422-2435.	5.1	25
128	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). Journal of Genetics and Genome Research, 2015, 2, .	0.3	25
129	Evaluation of the Effectiveness of the Minerva Cervicothoracic Orthosis. Spine, 1995, 20, 1475-1479.	2.0	24
130	Common variants at the <i>CHEK2 </i> gene locus and risk of epithelial ovarian cancer. Carcinogenesis, 2015, 36, 1341-1353.	2.8	24
131	Diet Quality Scores Inversely Associated with Postmenopausal Breast Cancer Risk Are Not Associated with Premenopausal Breast Cancer Risk in the California Teachers Study. Journal of Nutrition, 2018, 148, 1830-1837.	2.9	24
132	Pilot Study of Blood Biomarker Candidates for Detection of Pancreatic Cancer. Pancreas, 2010, 39, 981-988.	1.1	23
133	Polymorphism in the <i>GALNT1</i> Gene and Epithelial Ovarian Cancer in Non-Hispanic White Women: The Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 600-604.	2.5	23
134	Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Human Genetics, 2014, 133, 481-497.	3.8	23
135	Observed-to-expected ratio for adherence to treatment guidelines as a quality of care indicator for ovarian cancer. Gynecologic Oncology, 2015, 139, 495-499.	1.4	23
136	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 2017, 116, 524-535.	6.4	23
137	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	2.8	23
138	Role of Primary Tumor Resection Among Chemotherapy-Treated Patients with Synchronous Stage IV Colorectal Cancer: A Survival Analysis. Journal of Gastrointestinal Surgery, 2014, 18, 592-598.	1.7	22
139	Epithelialâ€Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology, 2015, 39, 689-697.	1.3	22
140	Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2019, 48, 822-830.	1.9	22
141	Age-dependent interaction between sex and geographic ultraviolet index in melanoma risk. Journal of the American Academy of Dermatology, 2020, 82, 1102-1108.e3.	1.2	22
142	Meat Consumption, Nonsteroidal Anti-Inflammatory Drug Use, and Mortality among Colorectal Cancer Patients in the California Teachers Study. Cancer Prevention Research, 2010, 3, 865-875.	1.5	21
143	Large-Scale Evaluation of Common Variation in Regulatory T Cell–Related Genes and Ovarian Cancer Outcome. Cancer Immunology Research, 2014, 2, 332-340.	3.4	21
144	Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 987-992.	2.5	20

#	Article	IF	Citations
145	The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. Cancer Epidemiology, 2016, 41, 71-79.	1.9	20
146	Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 174-182.	2.5	20
147	Survival of distinct Asian groups among colorectal cancer cases in California. Cancer, 2009, 115, 259-270.	4.1	19
148	Multilevel socioeconomic effects on quality of life in adolescent and young adult survivors of leukemia and lymphoma. Quality of Life Research, 2013, 22, 1339-1351.	3.1	19
149	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Human Genetics, 2016, 135, 741-756.	3.8	19
150	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078.	12.8	19
151	Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 623-642.	2.5	19
152	A genome-wide association study to identify genetic susceptibility loci that modify ductal and lobular postmenopausal breast cancer risk associated with menopausal hormone therapy use: a two-stage design with replication. Breast Cancer Research and Treatment, 2013, 138, 529-542.	2.5	18
153	Novel polymorphisms in caspase-8 are associated with breast cancer risk in the California Teachers Study. BMC Cancer, 2016, 16, 14.	2.6	18
154	Laminin 332 expression and prognosis in breast cancer. Human Pathology, 2018, 82, 289-296.	2.0	18
155	R5 Human Immunodeficiency Virus Type 1 Infection of Fetal Thymic Organ Culture Induces Cytokine and CCR5 Expression. Journal of Virology, 2005, 79, 458-471.	3.4	17
156	9q31.2-rs865686 as a Susceptibility Locus for Estrogen Receptor-Positive Breast Cancer: Evidence from the Breast Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1783-1791.	2.5	17
157	Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. Human Molecular Genetics, 2016, 25, 3600-3612.	2.9	17
158	Trends in Treatment Patterns and Clinical Outcomes in Young Women Diagnosed With Ductal Carcinoma In Situ. Clinical Breast Cancer, 2018, 18, e179-e185.	2.4	17
159	Cancer burden in four countries of the Middle East Cancer Consortium (Cyprus; Jordan; Israel; Izmir) Tj ETQq1 1 (Cancer Epidemiology, 2016, 44, 195-202.	0.784314 1.9	rgBT /Overlo 16
160	Measuring the quality of surgical decisions for Latina breast cancer patients. Health Expectations, 2015, 18, 2389-2400.	2.6	15
161	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology, 2015, 136, 542-548.	1.4	15
162	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. British Journal of Cancer, 2018, 118, 1123-1129.	6.4	15

#	Article	IF	Citations
163	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2018, 47, 450-459.	1.9	15
164	Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. Gynecologic Oncology, 2020, 158, 702-709.	1.4	15
165	Contribution of Geographic Location to Disparities in Ovarian Cancer Treatment. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1318-1329.	4.9	15
166	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. Breast Cancer Research, 2014, 16, R51.	5.0	14
167	Costs of treatment for elderly women with advanced ovarian cancer in a Medicare population. Gynecologic Oncology, 2015, 137, 479-484.	1.4	14
168	Perception matters: Stressful life events increase breast cancer risk. Journal of Psychosomatic Research, 2018, 110, 46-53.	2.6	14
169	Variation in NF-l̂ºB Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1421-1427.	2.5	13
170	The Association Between Circulating Total Folate and Folate Vitamers With Overall Survival After Postmenopausal Breast Cancer Diagnosis. Nutrition and Cancer, 2015, 67, 442-448.	2.0	13
171	Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. British Journal of Cancer, 2017, 116, 1223-1228.	6.4	13
172	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. Oncotarget, 2016, 7, 72381-72394.	1.8	13
173	Ascertainment Bias in Rate Ratio Estimation from Case-Sibling Control Studies of Variable Age-At-Onset Diseases. Biometrics, 1999, 55, 1129-1136.	1.4	12
174	A Comparison Study of Clinicopathologic Characteristics of Southern California Asian American Non-small Cell Lung Cancer (NSCLC) Patients by Smoking Status. Journal of Thoracic Oncology, 2010, 5, 158-168.	1.1	12
175	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. Human Molecular Genetics, 2014, 23, 6034-6046.	2.9	12
176	A comprehensive gene–environment interaction analysis in Ovarian Cancer using genomeâ€wide significant common variants. International Journal of Cancer, 2019, 144, 2192-2205.	5.1	12
177	A California Cancer Registry Analysis of Urothelial and Non-urothelial Bladder Cancer Subtypes: Epidemiology, Treatment, and Survival. Clinical Genitourinary Cancer, 2020, 18, e330-e336.	1.9	12
178	Multi-Systemic Biological Risk and Cancer Mortality: The NHANES III Study. Scientific Reports, 2020, 10, 5047.	3.3	12
179	A Risk-Adjusted Model for Ovarian Cancer Care and Disparities in Access to High-Performing Hospitals. Obstetrics and Gynecology, 2020, 135, 328-339.	2.4	11
180	Ambient air pollution and ovarian cancer survival in California. Gynecologic Oncology, 2021, 163, 155-161.	1.4	11

#	Article	IF	Citations
181	Better late than never: Brachytherapy is more important than timing in treatment of locally advanced cervical cancer. Gynecologic Oncology, 2022, 164, 348-356.	1.4	11
182	Cost-effectiveness of primary debulking surgery when compared to neoadjuvant chemotherapy in the management of stage III C and IV epithelial ovarian cancer. ClinicoEconomics and Outcomes Research, 2016, Volume 8, 397-406.	1.9	10
183	History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1470-1473.	2.5	10
184	A Case-Control Study of the Genetic Variability in Reactive Oxygen Speciesâ€"Metabolizing Enzymes in Melanoma Risk. International Journal of Molecular Sciences, 2018, 19, 242.	4.1	10
185	Evaluation of clear cell subtypes of ovarian and uterine malignancies with anti-PD-L1 and anti-PD1 immunohistochemical expression and their association with stage and survival. Gynecologic Oncology, 2019, 155, 483-488.	1.4	10
186	An inverse association between ovarian cysts and breast cancer in the breast cancer family registry. International Journal of Cancer, 2006, 118, 197-202.	5.1	9
187	Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 446-454.	2.5	9
188	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS ONE, 2018, 13, e0197561.	2.5	9
189	Secondhand smoke, obesity, and risk of type II diabetes among California teachers. Annals of Epidemiology, 2019, 32, 35-42.	1.9	9
190	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. British Journal of Cancer, 2021, 125, 1135-1145.	6.4	9
191	Association of Glyphosate Exposure with Blood DNA Methylation in a Cross-Sectional Study of Postmenopausal Women. Environmental Health Perspectives, 2022, 130, 47001.	6.0	9
192	Diet and predictors of dietary intakes in women with family history of breast and/or ovarian cancer. Cancer Epidemiology, 2009, 33, 419-423.	1.9	8
193	Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. American Journal of Epidemiology, 2018, 187, 366-377.	3.4	8
194	Implementation of human papillomavirus video education for women participating in mass cervical cancer screening in Tanzania. American Journal of Obstetrics and Gynecology, 2021, 224, 105.e1-105.e9.	1.3	8
195	Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies. Journal of the National Cancer Institute, 2021, 113, 301-308.	6.3	8
196	Disparities by race, socioeconomic status, and insurance type in the receipt of NCCN guideline concordant care for select cancer types in California Journal of Clinical Oncology, 2020, 38, 7031-7031.	1.6	8
197	Human Nail Clippings as a Source of DNA for Genetic Studies. Open Journal of Epidemiology, 2015, 05, 41-50.	0.4	8
198	Intent-to-Treat Analysis of Stage Ib and Ila Cervical Cancer in the United States. Obstetrics and Gynecology, 2001, 97, 248-254.	2.4	7

#	Article	IF	CITATIONS
199	Cancer risk in different generations of <scp>M</scp> iddle <scp>E</scp> astern immigrants to <scp>C</scp> alifornia, 1988–2013. International Journal of Cancer, 2017, 141, 2260-2269.	5.1	7
200	Ovarian cancer in California: Guideline adherence, survival, and the impact of geographic location, 1996–2014. Cancer Epidemiology, 2020, 69, 101825.	1.9	7
201	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Research, 2021, 23, 86.	5.0	7
202	A targeted genetic association study of epithelial ovarian cancer susceptibility. Oncotarget, 2016, 7, 7381-7389.	1.8	7
203	Clinical Implementation of a Breast Cancer Risk Assessment Program in a Multiethnic Patient Population: Which Risk Model to Use?. Breast Journal, 2015, 21, 562-564.	1.0	6
204	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. Cancer Medicine, 2019, 8, 2503-2513.	2.8	6
205	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. American Journal of Human Genetics, 2021, 108, 1190-1203.	6.2	6
206	Rare germline copy number variants (CNVs) and breast cancer risk. Communications Biology, 2022, 5, 65.	4.4	6
207	7q21-rs6964587 and breast cancer risk: an extended case-control study by the Breast Cancer Association Consortium. Journal of Medical Genetics, 2011, 48, 698-702.	3.2	5
208	Mortality Risk After Preoperative Versus Postoperative Chemotherapy and Radiotherapy in Lymph Node-Positive Rectal Cancer. Journal of Gastrointestinal Surgery, 2013, 17, 374-381.	1.7	5
209	Negative Valence Life Events Promote Breast Cancer Development. Clinical Breast Cancer, 2018, 18, e521-e528.	2.4	5
210	Breast Cancer Characteristics in Middle Eastern Women Immigrants Compared With Non-Hispanic White Women in California. JNCI Cancer Spectrum, 2018, 2, pky014.	2.9	5
211	Two truncating variants in FANCC and breast cancer risk. Scientific Reports, 2019, 9, 12524.	3.3	5
212	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. British Journal of Cancer, 2021, 124, 842-854.	6.4	5
213	Polymorphisms in Stromal Genes and Susceptibility to Serous Epithelial Ovarian Cancer: A Report from the Ovarian Cancer Association Consortium. PLoS ONE, 2011, 6, e19642.	2.5	5
214	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 2016, 7, 69097-69110.	1.8	5
215	Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association. Gynecologic Oncology, 2021, , .	1.4	5
216	Timing of Radiation Therapy, Lymph Node Retrieval, and Survival in Rectal Cancer. Diseases of the Colon and Rectum, 2011, 54, 526-534.	1.3	4

#	Article	IF	CITATIONS
217	Nonparametric Adjustment for Measurement Error in Time-to-Event Data: Application to Risk Prediction Models. Journal of the American Statistical Association, 2018, 113, 14-25.	3.1	4
218	Ocular Tonometry and Sporadic Creutzfeldt - Jakob disease (sCJD): A Confirmatory Case-Control Study. British Journal of Medicine and Medical Research, 2014, 4, 2322-2333.	0.2	4
219	Mammography screening and mortality by risk status in the California teachers study. BMC Cancer, 2021, 21, 1341.	2.6	4
220	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 420-424.	2.5	3
221	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal of Molecular Sciences, 2018, 19, 2473.	4.1	3
222	Rationale, Study Design, and Cohort Characteristics for the Markers for Environmental Exposures (MEE) Study. International Journal of Environmental Research and Public Health, 2020, 17, 1774.	2.6	3
223	Association of mammographic density with blood DNA methylation. Epigenetics, 2021, , 1-16.	2.7	3
224	Dietary Risk Factors for Sporadic Creutzfeldt-Jakob Disease: A Confirmatory Case-Control Study. British Journal of Medicine and Medical Research, 2014, 4, 2388-2417.	0.2	3
225	Identification of a gene expression signature predicting survival in oral cavity squamous cell carcinoma using Monte Carlo cross validation. Oral Oncology, 2018, 78, 72-79.	1.5	2
226	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Scientific Reports, 2020, 10, 9688.	3.3	2
227	Comparison of Perioperative Outcomes for Radical Nephrectomy Based on Surgical Approach for Masses Greater than 10cm. Journal of Endourology, 2021, 35, 1785-1792.	2.1	2
228	Surgery as women's work: gender in presentations at gynecologic conferences. American Journal of Obstetrics and Gynecology, 2021, 225, 454-455.	1.3	2
229	Feasibility of visual inspection with acetic acid (VIA) screening for cervical cancer in Tanzania with emphasis on special populations Journal of Clinical Oncology, 2019, 37, 5527-5527.	1.6	2
230	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. Scientific Reports, 2021, 11, 19787.	3.3	2
231	Retrospective Comparison of Simultaneous and Non-Simultaneous Bilateral Radial Keratotomy. Journal of Refractive Surgery, 1994, 10, 545-549.	2.3	2
232	High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 443-452.	2.5	2
233	Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women. Scientific Reports, 2022, 12, 6199.	3.3	2
234	Imputation of Missing Ages in Pedigree Data. Human Heredity, 2007, 63, 168-174.	0.8	1

#	Article	IF	CITATIONS
235	Factors Associated with Women's Unwillingness to Decrease Alcohol Intake to Decrease Breast Cancer Risk. Journal of Primary Care and Community Health, 2021, 12, 215013272110002.	2.1	1
236	Visual inspection with acetic acid screening for cervical cancer among women receiving antiâ€retroviral therapy for human immunodeficiency virus infection in northernÂTanzania. Journal of Obstetrics and Gynaecology Research, 2021, 47, 4365-4370.	1.3	1
237	RESPONSE: Re: Characterization of Hereditary Nonpolyposis Colorectal Cancer Families From a Population-Based Series of Cases. Journal of the National Cancer Institute, 2001, 93, 717-717.	6.3	O
238	Analysis of Prognostic Factors in Chordoma Using the California Cancer Registry. Spine Journal, 2010, 10, S103-S104.	1.3	0
239	Prostate Cancer Susceptibility Polymorphism rs2660753 Is Not Associated with Invasive Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1028-1031.	2.5	0
240	Genome-Wide Testing of Exonic Variants and Breast Cancer Risk in the California Teachers Study. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1462-1465.	2.5	0
241	Impact of the affordable care act (ACA) Medicaid expansion on early stage diagnosis and guideline-adherent care for ovarian cancer patients in California. Gynecologic Oncology, 2020, 159, e18-e19.	1.4	0
242	Complicated placenta accreta spectrum: identifying a high-risk cohort. Journal of Maternal-Fetal and Neonatal Medicine, 2021, , 1-9.	1. 5	0
243	Rrp1b, a new candidate susceptibility gene for breast cancer progression and metastasis. PLoS Genetics, 2005, preprint, e214.	3.5	0
244	Elevated plasma folate concentrations and dietary folate are associated with overall survival after breast cancer diagnosis. FASEB Journal, 2008, 22, 775-775.	0.5	0
245	Survival benefits of adjuvant chemotherapy in high-grade stage II and III colon cancer Journal of Clinical Oncology, 2013, 31, e14529-e14529.	1.6	0
246	Evaluation of unanticipated 30-day readmission in patients with advanced stage epithelial ovarian cancer Journal of Clinical Oncology, 2015, 33, e17684-e17684.	1.6	0
247	Gender difference in the association of melanoma etiology to solar UV exposure Journal of Clinical Oncology, 2015, 33, e20012-e20012.	1.6	0
248	Population-based analysis of guideline adherence for patients with rectal cancer in California Journal of Clinical Oncology, 2020, 38, e19045-e19045.	1.6	0
249	Relationship of the breast ductal carcinoma in situ (DCIS) immune microenvironment with clinicopathological features: An institutional experience Journal of Clinical Oncology, 2020, 38, e12565-e12565.	1.6	0
250	Disparities in the receipt of National Comprehensive Cancer Network (NCCN) guideline adherent care in triple-negative breast cancer (TNBC) by race/ethnicity, socioeconomic status, and insurance type Journal of Clinical Oncology, 2020, 38, 1080-1080.	1.6	0